Estrogen receptor degrader increases progression-free survival in advanced breast can

[News]

Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, researchers reported at the ESMO 2016 Congress in Copenhagen

More... (http://www.news-medical.net/news/20161008/Estrogen-receptor-degrader-increases-progression-free-survival-in-advanced-breast-cancer-patients.aspx)

[Melissa]

New option?

Does this mean since I take arimidix that this is a new option for me???
Thanks,

[Becky]

This is Faslodex and has been around forever. I think it is only for stage 4 disease.